A rapid antidote for methamphetamine intoxication that can be given by IV
Official title: A Phase 2a clinical study to evaluate the safety and efficacy of CS-1103, a therapeutic agent to treat methamphetamine intoxication
Funded at Clear Scientific, LLC · NIH-11391457 · Data updated 2026-11-12
A phase 2a study tests CS-1103, a fast-acting treatment designed to reverse methamphetamine intoxication and help clear the drug from the body.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Clear Scientific, LLC NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $3,000,030 |
| NIH project number | 1U01DA066075-01 |
| Project ID | NIH-11391457 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with known or suspected methamphetamine intoxication presenting to clinical care.
✕Less likely to help
Patients without meth intoxication or those who experience severe adverse reactions may not benefit.
What this research studies
This study aims to determine if CS-1103 can quickly reverse the symptoms of methamphetamine overdose and accelerate drug clearance in patients who present with intoxication. It uses an IV formulation to rapidly act in the bloodstream and central nervous system, with safety and preliminary efficacy as the main outcomes. If successful, this could provide clinicians with a new tool to treat meth-related emergencies and reduce hospital stays.
Why it matters
Potential benefit: If CS-1103 works as hoped, patients could recover faster from meth intoxication and experience fewer complications.
How similar studies have gone: Previous nonclinical work and early steps have supported development, but this is an early human trial with novel dual-action mechanism.
Where this research is happening
-
Clear Scientific, LLC
Cambridge, United States Active
Researchers
- Principal investigator: Li, Xinhua — Clear Scientific, LLC
- Study coordinator: Li, Xinhua
Related research
Other NIH-funded projects on the same topics.
-
A new medicine to quickly reverse methamphetamine overdose
This project aims to develop a fast-acting medicine called CS-1103 to help people experiencing severe methamphetamine intoxication.
-
New antidote for overdoses involving fentanyl and xylazine
A new injectable medicine that quickly removes both fentanyl and xylazine to reverse sedation and breathing problems in people overdosing on these drugs.
-
A new treatment to quickly remove synthetic opioids from the body
This study is testing a new treatment called CS-1103 that helps quickly remove dangerous synthetic opioids like fentanyl from the body, aiming to provide a single dose that can restore normal breathing and keep people safe after an overdose.
-
Developing a new antidote for fentanyl and xylazine overdoses
This study is working on a new treatment to help people who have overdosed on a mix of fentanyl and xylazine, which regular naloxone can't fix, so that they can breathe better and feel more alert again.
-
Developing a fast-acting antidote for methamphetamine overdose
This study is testing a new treatment called CS-1103 that helps quickly remove methamphetamine from the body, making it safer for people who have overdosed on the drug, and it's aimed at helping emergency departments handle these situations better.
-
New treatment to reverse opioid overdose
This study is testing a new injection called CS-1103 that aims to quickly reverse the effects of fentanyl overdoses, offering a potentially better option than the usual treatment, naloxone, for people who might need help in an emergency.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.